Yours Free! Top FIVE Dividend Stocks Right Now
This Ultimate Dividend Package contains an "A"-rated, ultra-safe dividend stock with a huge 8% yield, and one income expert's No. 1 dividend stock for a LIFETIME of income. 

Click here to get your FREE Ultimate Dividend Package.
Pankaj Mohan net worth and biography

Pankaj Mohan Biography and Net Worth

Dr. Pankaj Mohan founded Sonnet in 2015 and currently serves as Chief Executive Officer and Chairman. He is also a member of the Board of Directors of Outlook Therapeutics, Inc. which he also founded (formerly known as Oncobiologics). From January 2011 to June 2018, he served as Oncobiologics’ President, Chief Executive Officer, and Chairman. Previously, Dr. Mohan served as head of Business Operations and Portfolio Management of Biologics Process and Product Development at Bristol-Myers Squibb Company and as a Director of Bioprocess Engineering at Genentech, Inc. Prior to that Dr. Mohan served as a senior manager at Eli Lilly and Company. From May 1993 to April 1996, Dr. Mohan served as Assistant Professor (Lecturer/Fellow) at the Advanced Centre for Biochemical Engineering, University College London, London, United Kingdom.

Dr. Mohan received a Doctor of Philosophy in Biochemical Engineering from the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom, a master’s in financial management from Middlesex University Business School, London, United Kingdom, and a bachelor’s degree in chemical engineering from the Indian Institute of Technology in Roorkee, India. Dr. Mohan also attended an Executive Management Program (AMP) from Fuqua School of Business at Duke University.

What is Pankaj Mohan's net worth?

The estimated net worth of Pankaj Mohan is at least $240,366.99 as of May 15th, 2023. Dr. Mohan owns 553,331 shares of Sonnet BioTherapeutics stock worth more than $240,367 as of June 7th. This net worth approximation does not reflect any other assets that Dr. Mohan may own. Additionally, Dr. Mohan receives an annual salary of $792,170.00 as CEO at Sonnet BioTherapeutics. Learn More about Pankaj Mohan's net worth.

How old is Pankaj Mohan?

Dr. Mohan is currently 58 years old. There are 5 older executives and no younger executives at Sonnet BioTherapeutics. Learn More on Pankaj Mohan's age.

What is Pankaj Mohan's salary?

As the CEO of Sonnet BioTherapeutics Holdings, Inc., Dr. Mohan earned a total compensation package of $792,165.00 in 2021. Dr. Mohan earned a salary of $512,236.00, a bonus of $279,930.00, and no other miscellaneous compensation. Learn More on Pankaj Mohan's salary.

How do I contact Pankaj Mohan?

The corporate mailing address for Dr. Mohan and other Sonnet BioTherapeutics executives is 100 OVERLOOK CENTER SUITE 102, PRINCETON NJ, 08540. Sonnet BioTherapeutics can also be reached via phone at 609-375-2227 and via email at [email protected]. Learn More on Pankaj Mohan's contact information.

Has Pankaj Mohan been buying or selling shares of Sonnet BioTherapeutics?

Over the course of the past ninety days, Pankaj Mohan has bought $81,752.00 in Sonnet BioTherapeutics stock. Most recently, on Monday, May 15th, Pankaj Mohan bought 371,600 shares of Sonnet BioTherapeutics stock. The stock was acquired at an average cost of $0.22 per share, with a total value of $81,752.00. Following the completion of the transaction, the chief executive officer now directly owns 553,331 shares of the company's stock, valued at $121,732.82. Learn More on Pankaj Mohan's trading history.

Who are Sonnet BioTherapeutics' active insiders?

Sonnet BioTherapeutics' insider roster includes Richard Kenney (Insider), and Pankaj Mohan (CEO). Learn More on Sonnet BioTherapeutics' active insiders.

Are insiders buying or selling shares of Sonnet BioTherapeutics?

In the last year, Sonnet BioTherapeutics insiders bought shares 3 times. They purchased a total of 419,855 shares worth more than $98,431.85. The most recent insider tranaction occured on May, 30th when Director Albert D Dyrness bought 23,255 shares worth more than $10,929.85. Insiders at Sonnet BioTherapeutics own 3.0% of the company. Learn More about insider trades at Sonnet BioTherapeutics.

Information on this page was last updated on 5/30/2023.

Pankaj Mohan Insider Trading History at Sonnet BioTherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2023Buy371,600$0.22$81,752.00553,331View SEC Filing Icon  
6/9/2021Buy32,000$1.55$49,600.00View SEC Filing Icon  
See Full Table

Pankaj Mohan Buying and Selling Activity at Sonnet BioTherapeutics

This chart shows Pankaj Mohan's buying and selling at Sonnet BioTherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sonnet BioTherapeutics Company Overview

Sonnet BioTherapeutics logo
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $0.43
Low: $0.42
High: $0.47

50 Day Range

MA: $0.32
Low: $0.22
High: $0.51

2 Week Range

Now: $0.43
Low: $0.21
High: $4.56


2,192,136 shs

Average Volume

2,025,185 shs

Market Capitalization

$11.94 million

P/E Ratio


Dividend Yield